Please ensure Javascript is enabled for purposes of website accessibility

Why Insys Therapeutics Shares Got Trounced in January

By Todd Campbell – Feb 2, 2016 at 7:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Risk associated with improper off-label marketing allegations led to investors selling their shares last month.

Image source: Insys Therapeutics.

What: Amid ongoing concern that regulatory scrutiny over its marketing practices could erode demand for its fast-growing cancer drug and lead to profit unfriendly settlements, investors sent shares in Insys Therapeutics (INSY) reeling by 39.4% in January, according to S&P Capital IQ.

So what: Insys has been on the hot seat for marketing practices associated with its fast-growing opioid cancer drug Subsys.

Subsys won Food and Drug Administration approval in 2012 and it has since become the top-selling fentanyl opioid pain drug in the country, with third-quarter sales exceeding $91 million, up 57% from a year ago.

However, investigations are ongoing to determine whether Insys Therapeutics bulked up sales by marketing Subsys to doctors as a therapy for use in patients suffering from conditions that aren't listed on its label. Although doctors have the freedom to prescribe medicine off-label, drugmakers are prohibited from marketing their drugs for such use. 

Image source: Insys Therapeutics.

Now what: Investor concern has spiked following a $1.1 million settlement with Oregon's attorney general last fall and reports that the company's prescription support center helped push through reimbursement for non-cancer indications.

So far, however, the cloud hanging over Insys Therapeutics HQ hasn't dented Subsys sales or Insys Therapeutics' profitability. In the first nine months of 2015, the company's net income totaled $41.5 million, up from $28.6 million in the comparable period of 2014.

Obviously, it's unknown how all this is going to shake out and what -- if any -- penalties may be looming, but there are some reasons why risk-tolerant investors may want to consider picking up Insys Therapeutics' shares on sale.

Insys Therapeutics' oral formulation of the long-standing HIV and cancer nausea drug marinol is one reason. The FDA is expected to issue an approval decision on Insys Therapeutics' formulation in the next few months, and if approved, Insys Therapeutics thinks it could have nine-figure sales potential.

Insys Therapeutics' sales could also eventually benefit from research underway on marijuana-based therapies for epilepsy and from other medicines the company is working on that leverage Subsys spray technology.

Overall, Insys Therapeutics' profitability, debt-free balance sheet, and potential products make its shares intriguing, but it's unlikely that they'll move markedly higher until it can put this overhang behind it. 


Todd Campbell owns shares of Insys Therapeutics. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

INSYS Therapeutics Stock Quote
INSYS Therapeutics

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.